VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. AIG INSURANCE COMPANY OF CANADA

CourtDistrict Court, D. New Jersey
DecidedJanuary 5, 2023
Docket3:18-cv-00493
StatusUnknown

This text of VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. AIG INSURANCE COMPANY OF CANADA (VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. AIG INSURANCE COMPANY OF CANADA) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. AIG INSURANCE COMPANY OF CANADA, (D.N.J. 2023).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

VALEANT PHARMACEUTICALS INTERNATIONAL, INC., ef al., intiff: Plaintitfs, Civil Action No. 18-493 (MAS) (RLS) v. MEMORANDUM OPINION AIG INSURANCE COMPANY OF CANADA et al., Defendants.

SHIPP, District Judge This matter comes before the Court on Defendant Allianz Global Risks US Insurance Company’s (“Allianz”) Motion to Certify the Court’s September 6, 2022, Order for Interlocutory Appeal Pursuant to 28 U.S.C. § 1292(b), to which a group of insurer Defendants joined. (ECF No. 315.)' Plaintiffs Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, and AGMS, Inc. (collectively, the “Valeant Entities”) opposed (ECF No. 324), and Allianz replied (ECF No. 325).” The Court has carefully considered the parties’ submissions and

! Specifically, the following Defendants joined Allianz’s Motion: (1) Hartford Fire Insurance Company; (2) Arch Insurance Canada Ltd.; (3) Everest Insurance Company of Canada; (4) Liberty International Underwriters, a division of Liberty Mutual Insurance Company, Royal & Sun Alliance Insurance Company of Canada, Certain Underwriters at Lloyd’s, London subscribing to Policy No. QBNO078613, and Certain Underwriters at Lloyd’s, London subscribing to policy No. QB078913; and (5) Temple Insurance Company, and Certain Underwriters at Lloyd’s, London subscribing to Policy No. QB146013. * The same Defendants that joined Allianz’s Motion joined Allianz’s Reply. (ECF No. 325.)

decides the matter without oral argument pursuant to Local Civil Rule 78.1. For the reasons set forth below, the Court denies Allianz’s Motion. 1. BACKGROUND The Court provided a comprehensive overview of the factual allegations giving rise to this action in its Memorandum Opinion accompanying the September 6, 2022 Order (the “September Order,” ECF No. 314) and incorporates that background herein. (See Mem. Op. 2-26, ECF No. 313.) The Valeant Entities stand accused of manipulating the securities of Allergan, Inc., (“Allergan”) by conspiring with a third party to withhold news of a pending exchange offer by the Valeant Entities, thus damaging Allergan’s shareholders. (See id. at 21.) Originally at issue, prior to the September Order, was whether claims asserted in the underlying insider trading suit brought pursuant to the Williams Act against the Valeant Entities constitute “Securities Claims” under provisions of the Valeant Entities’ 2013-2014 insurance policy (the “Policy”) and excessive coverage policies.’ (See id. at 2, 17.) In relevant part, the Policy defines a “Securities Claim” as: a Claim, other than an administrative or regulatory proceeding against, or investigation of an Organization, made against any Insured: (1) alleging a violation of any law, rule or regulation, whether statutory or common law (including but not limited to the purchase or sale or offer or solicitation of an offer to purchase or sell securities), which is: (a) brought by any person or entity alleging, arising out of, based upon or attributable to the purchase or sale or offer or solicitation of an offer to purchase or sell any securities of an Organization; or (b) brought by a security holder or purchaser or seller of securities of an Organization with respect to such

3 Accordingly, references throughout this Memorandum Opinion to the Policy are coextensive with the 2013-2014 excess coverage policies.

security holder’s, purchaser’s or seller’s interest in securities of such Organization; or (2) which is a Derivative Suit. (Policy *11, *68, ECF No. 233-3.)* In dispute was whether the underlying insider trading claims against the Valeant Entities “allege, arise out of, are based upon, or are attributable to an offer to sell Valeant securities” triggering coverage under section l(a) of the Policy. (Mem. Op. 18.) Notably, this case differs from typical insider trading cases because, here, the Valeant Entities are accused of manipulating a different company’s—Allergan’s—securities, so the connection to the Valeant Entities’ securities is “somewhat murky.” (/d. at 21.) The Court, utilizing standardized insurance contract interpretation, opined that the claims against the Valeant Entities constituted Securities Claims under the Policy. (/d. at 27.) The Court afforded each word in the Policy its plain and ordinary meaning, strived to adopt interpretations consistent with the reasonable expectations of the parties, and considered the preference given to the insured when the Policy’s language was ambiguous. (/d. at 27-28.) Allianz now moves to certify the September Order for interlocutory appeal contending that the Policy does not cover the claims against the Valeant Entities. Allianz argues that the issue in the September Order meets the three criteria for certification under 28 U.S.C. § 1292(b). (Allianz’s Moving Br. 3-4, ECF No, 315-1.) Allianz further asserts that this issue is a matter of “significant public importance” to insurance companies and their insured. (/d. at 3-5.) According to the Valeant Entities, this is not an “exceptional” case that warrants interlocutory appeal, and it does not meet any of the required criteria. (Valent Entities’ Opp’n Br. 2-4, ECF No. 324.)

Although the Policy is separately paginated, the Court pin-cites it through the pagination atop the CM/ECF header for ease of reference. Pin-cites prefaced by asterisks refer to the CM/ECF pagination.

I. LEGAL STANDARD Generally, a matter may not be appealed to the Third Circuit until a final judgment has been rendered. Kaplan v. Saint Peter’s Healthcare Sys., No. 13-2941, 2014 WL 4678059, at *2 (D.N.J. Sept. 19, 2014). An interlocutory appeal, however, may be proper in “exceptional cases” where forgoing the normal procedure of appealing after final judgment is appropriate. Caterpillar Ine. v. Lewis, 519 U.S. 61, 74 (1996). Thus, under § 1292(b), the Court may exercise its discretion in certifying an order for interlocutory appeal if the order (1) “involves a controlling question of law,” (2) “as to which there is substantial ground for difference of opinion,” and (3) “an immediate appeal from the order may materially advance the ultimate termination of the litigation.” 28 U.S.C. § 1292(b); F.T-C. v. Wyndham Worldwide Corp., 10 F. Supp. 3d 602, 633 (D.N.J. 2014). But even if all three criteria are met, certification is not mandatory, rather, it is “wholly discretionary.” Juice Ent., LLC v. Live Nation Ent., Inc., 353 F. Supp. 3d 309, 312 (D.N.J. 2018) (quoting P. Schoenfeld Asset Mgmt. LLC vy. Cendant Corp., 161 F. Supp. 2d 355, 358 (D.N.J. 2001)). The burden to demonstrate that certification is proper lies with the moving party. Kapossy v. McGraw-Hill Inc., 942 F. Supp. 996, 1001 (D.N.J. 1996). And, importantly, “[i]n evaluating these factors, ‘[a] motion [for certification] should not be granted merely because a party disagrees with the ruling of the district judge.” Jd. (quoting Max Daetwyler Corp. v. Meyer, 575 F. Supp. 280, 282 (E.D. Pa. 1983)). Il. DISCUSSION Allianz moves to certify the September Order for interlocutory appeal. The Court addresses each factor required for certification below.

A.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Caterpillar Inc. v. Lewis
519 U.S. 61 (Supreme Court, 1996)
Max Daetwyler Corp. v. Meyer
575 F. Supp. 280 (E.D. Pennsylvania, 1983)
Hulmes v. Honda Motor Company, Ltd.
936 F. Supp. 195 (D. New Jersey, 1996)
Kapossy v. McGraw-Hill, Inc.
942 F. Supp. 996 (D. New Jersey, 1996)
P. Schoenfeld Asset Management LLC v. Cendant Corp.
161 F. Supp. 2d 355 (D. New Jersey, 2001)
Federal Trade Commission v. Wyndham Worldwide Corp.
10 F. Supp. 3d 602 (D. New Jersey, 2014)
Juice Entm't, LLC v. Live Nation Entm't, Inc.
353 F. Supp. 3d 309 (D. New Jersey, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. AIG INSURANCE COMPANY OF CANADA, Counsel Stack Legal Research, https://law.counselstack.com/opinion/valeant-pharmaceuticals-international-inc-v-aig-insurance-company-of-njd-2023.